Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Patient Care Eli Lilly Phase 3 Trials Patient Outcomes FDA Regulations Regulatory Approval Fast Track Designation by FDA Novo Nordisk Regulatory Affairs Phase 2 Trials

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

A finite six‑month regimen raises hopes for a functional cure in a disease usually managed with lifelong antivirals.

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion